June 1, 2012
- Kasznar Leonardos
Newsletter 2012.03 – The debate over ANVISA’s role in the examination of pharmaceutical patent applications continues
As you may be aware, due to article 229-C of the Brazilian IP Law, as amended by Law No. 10,196/01, whenever a patent application claims a pharmaceutical product or process, consent from the National Sanitary Surveillance Agency (ANVISA) is also required prior to granting the desired patent. This provision, however, has been the source of never-ending controversy and subject to growing attacks since it entered into effect in 2001.
The lack of statutory power of ANVISA to analyse patentability requirements of pharma applications was supported by the Attorney-General’s Office in legal opinions published in 2009 and 2011. Indeed, in their opinion, ANVISA should only make health-based assessments of applications sent for prior consent; prior consent should only be denied to applications in instances that granting the patents would pose health risks. How ANVISA would assess “health risks” on the basis of the information included in patent applications was left unanswered though.
Last related news
November 22, 2021
Kasznar Leonardos receives ISO 9001 certification of quality
The ISO 9001 standard recognizes operational efficiency, focusing specifically on excellent customer service and continual process improvement. Our firm has received ISO … Kasznar Leonardos receives ISO 9001 certification of quality
November 12, 2021
BPTO recognizes the Right of Precedence as an argument for filing Administrative Nullities
By Flávia Tremura and Isabella Faccioli From November 2021 the BPTO will start to accept the right of precedence of the trademark … BPTO recognizes the Right of Precedence as an argument for filing Administrative Nullities
September 3, 2021
The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil
On Sept. 2nd, 2021, Law No 14,200 was enacted to amend the Brazilian Patent & Trademark Act (BPTA) in order to change … The Covid-19 pandemic triggered the issuance of new compulsory license rules for patents in Brazil